Valmark Advisers Inc. Lowers Position in CVS Health Corporation $CVS

Valmark Advisers Inc. cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 23.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,441 shares of the pharmacy operator’s stock after selling 1,074 shares during the period. Valmark Advisers Inc.’s holdings in CVS Health were worth $237,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of CVS. Bell Investment Advisors Inc lifted its position in CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 248 shares in the last quarter. Roxbury Financial LLC lifted its position in CVS Health by 78.3% during the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 202 shares in the last quarter. ORG Partners LLC lifted its position in CVS Health by 418.9% during the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 377 shares in the last quarter. Saudi Central Bank purchased a new position in shares of CVS Health in the first quarter valued at about $34,000. Finally, Livelsberger Financial Advisory purchased a new position in shares of CVS Health in the second quarter valued at about $35,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Up 1.5%

Shares of CVS stock opened at $77.89 on Friday. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $79.20. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The stock’s 50-day moving average price is $72.28 and its 200-day moving average price is $67.67. The stock has a market capitalization of $98.79 billion, a price-to-earnings ratio of 21.76, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The company had revenue of $98.92 billion for the quarter, compared to analysts’ expectations of $94.87 billion. During the same period in the previous year, the firm posted $1.83 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s payout ratio is presently 74.30%.

Insiders Place Their Bets

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.22% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CVS shares. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Sunday, September 21st. Jefferies Financial Group boosted their price objective on CVS Health from $74.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, June 30th. Bernstein Bank lowered their price objective on CVS Health from $78.00 to $72.00 and set a “market perform” rating on the stock in a research report on Wednesday, July 16th. Barclays boosted their price objective on CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research report on Thursday, September 4th. Finally, Morgan Stanley lifted their target price on CVS Health from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average target price of $79.80.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.